CHARLES F. WINKLER, M.D.; MERLE M. MAHR, M.D.; HARRY DEBANDI, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: The efficacy of cisplatin (cis-diamminedichloroplatinum II) in the treatment of solid tumors as well as the side-effects of the agent have been reported. Included in these side-effects are hyperuricemia and hypokalemia (1) Drs. Schilsky and Anderson (2) report an unknown complication of hypomagnesemia and renal magnesium wasting in patients receiving cisplatin in which withdrawal of the cisplatin was associated with normalization of serum magnesemia and absence of renal magnesium wasting. We wish to report an extreme case of hypomagnesemic hypocalcemic tetany with marked hypokalemia secondary to cisplatin in which the drug was continued and electrolyte losses were
WINKLER CF, MAHR MM, DEBANDI H. Cisplatin and Renal Magnesium Wasting. Ann Intern Med. 1979;91:502–503. doi: 10.7326/0003-4819-91-3-502_2
Download citation file:
Published: Ann Intern Med. 1979;91(3):502-503.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use